Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogen...

Full description

Bibliographic Details
Main Authors: Donata Backhaus, Madlen Jentzsch, Lara Bischof, Dominic Brauer, Christina Wilhelm, Julia Schulz, Georg-Nikolaus Franke, Wolfram Pönisch, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
trisomy 8
AML
allogeneic HSCT
MRD
Online Access:https://www.mdpi.com/2072-6694/13/22/5679

Internet

https://www.mdpi.com/2072-6694/13/22/5679

Similar Items